Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.

Beigi R, Noguchi L, Parsons T, Macio I, Kunjara Na Ayudhya RP, Chen J, Hendrix CW, Mâsse B, Valentine M, Piper J, Watts DH.

J Infect Dis. 2011 Nov 15;204(10):1527-31. doi: 10.1093/infdis/jir562. Epub 2011 Sep 19.

2.

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.

Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, Gomez K, Richardson BA, Bumpus NN.

PLoS One. 2013;8(1):e55013. doi: 10.1371/journal.pone.0055013. Epub 2013 Jan 30.

3.

A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.

Yang KH, Hendrix C, Bumpus N, Elliott J, Tanner K, Mauck C, Cranston R, McGowan I, Richardson-Harman N, Anton PA, Kashuba AD.

PLoS One. 2014 Oct 28;9(10):e106196. doi: 10.1371/journal.pone.0106196. eCollection 2014.

4.

Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.

Dobard C, Sharma S, Martin A, Pau CP, Holder A, Kuklenyik Z, Lipscomb J, Hanson DL, Smith J, Novembre FJ, García-Lerma JG, Heneine W.

J Virol. 2012 Jan;86(2):718-25. doi: 10.1128/JVI.05842-11. Epub 2011 Nov 9.

5.

RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.

Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, Elliott J, Janocko L, Khanukhova E, Dennis R, Cumberland WG, Ju C, Carballo-Diéguez A, Mauck C, McGowan I.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1412-21. doi: 10.1089/AID.2012.0262. Epub 2012 Oct 9.

6.

Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.

Clark MR, Friend DR.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1458-66. doi: 10.1089/AID.2011.0328. Epub 2012 Apr 17.

PMID:
22394281
7.

Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.

Nirogi R, Bhyrapuneni G, Kandikere V, Muddana N, Saralaya R, Komarneni P, Mudigonda K, Mukkanti K.

Biopharm Drug Dispos. 2012 Jul;33(5):265-77. doi: 10.1002/bdd.1794. Epub 2012 Jun 20.

PMID:
22610784
8.

Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.

Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E Jr, Cotter A, Purswani M; PACTG 394 Study Team..

Antimicrob Agents Chemother. 2011 Dec;55(12):5914-22. doi: 10.1128/AAC.00544-11. Epub 2011 Sep 6.

9.

A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.

Johnson TJ, Clark MR, Albright TH, Nebeker JS, Tuitupou AL, Clark JT, Fabian J, McCabe RT, Chandra N, Doncel GF, Friend DR, Kiser PF.

Antimicrob Agents Chemother. 2012 Dec;56(12):6272-83. doi: 10.1128/AAC.01431-12. Epub 2012 Sep 24.

10.

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.

Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, Poindexter A, Kearney BP.

PLoS One. 2011;6(10):e25974. doi: 10.1371/journal.pone.0025974. Epub 2011 Oct 19.

11.

Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.

Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, Anderson JR, Everts S, Bakshi R, Fuchs EJ, Hendrix CW.

AIDS Res Hum Retroviruses. 2013 Nov;29(11):1443-50. doi: 10.1089/AID.2013.0044. Epub 2013 May 29.

12.

Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study.

Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint NA, Tannenbaum SR, Hendrix CW, Fuchs EJ.

J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):593-9. doi: 10.1097/QAI.0b013e3182717c98.

13.

Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.

Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, Mohabeer M, Gazzard B, Boffito M.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):275-81. doi: 10.1097/QAI.0b013e3182829bd0.

PMID:
23274933
14.

Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.

Gao Y, Katz DF.

PLoS One. 2013 Sep 11;8(9):e74404. doi: 10.1371/journal.pone.0074404. eCollection 2013.

15.

Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques.

Pereira LE, Clark MR, Friend DR, Garber DA, McNicholl JM, Hendry RM, Doncel GF, Smith JM.

Antimicrob Agents Chemother. 2014 May;58(5):2665-74. doi: 10.1128/AAC.02336-13. Epub 2014 Feb 24.

16.

Vaginal deployment and tenofovir delivery by microbicide gels.

Gao Y, Yuan A, Chuchuen O, Ham A, Yang KH, Katz DF.

Drug Deliv Transl Res. 2015 Jun;5(3):279-94. doi: 10.1007/s13346-015-0227-1.

17.

Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.

Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, Pinto J, Santos B, Parsons T, Kearney B, Emel L, Herron C, Richardson P, Hudelson SE, Eshleman SH, George K, Fowler MG, Sato P, Mofenson L; HPTN 057 Protocol Team..

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):33-41. doi: 10.1097/QAI.0b013e3182a921eb.

18.

Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?

Adams JL, Sykes C, Menezes P, Prince HM, Patterson KB, Fransen K, Crucitti T, De Baetselier I, Van Damme L, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):260-6. doi: 10.1097/QAI.0b013e3182794723.

19.

Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Baheti G, King JR, Acosta EP, Fletcher CV.

AIDS. 2013 Jan 14;27(2):221-5. doi: 10.1097/QAD.0b013e32835a9a2d.

20.

Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.

Moss JA, Srinivasan P, Smith TJ, Butkyavichene I, Lopez G, Brooks AA, Martin A, Dinh CT, Smith JM, Baum MM.

Antimicrob Agents Chemother. 2014 Sep;58(9):5125-35. doi: 10.1128/AAC.02871-14. Epub 2014 Jun 16.

Supplemental Content

Support Center